Search Results

A phase 1/2 study of DR-01, an anti-CD94 monoclonal antibody, in patients with large granular lymphocytic leukemia or cytotoxic lymphomas

In November , LLS made an equity investment in Dren Bio to "Support Clinical Development of the Program for Rare Leukemia & Lymphoma Indications Incl…

Dren Bio

Dren Bio is a biopharmaceutical company focused on developing therapeutic antibodies for the treatment of cancer, autoimmune and other serious diseas…

Suggested Reading - Life Blood

Cathy Koning's moving, unflinchingly honest and often humorous recollections and reflections chart her experience from shock diagnosis of AML in to c…

ImCheck Presents Initial Patient Data from the EVICTION-2 Clinical Trial at SITC Annual Meeting

Marseille, France, November , – ImCheck Therapeutics presented today the first patient data from , a Phase I/II clinical trial evaluating the combina…

Applying Genomics and Biomarker Testing in Caring for Patients with Blood Cancer: A Primer for Healthcare Providers

Precision medicine is an emerging approach for prediction of disease risk and disease treatment afforded by the delivery of more precise and efficient…

Non-Accredited Videos, Webinars and Fact Sheets

The Leukemia & Lymphoma Society offers a range of free educational, resources for healthcare professionals.

FDA Approves New Targeted Treatment Option for Certain Forms of Acute Myeloid Leukemia in Adults

The U.S. Food and Drug Administration (FDA) granted approval yesterday to olutasidenib (Rezlidhia™) for the treatment of adults with acute myeloid leu…

Tessa

Tessa surprised our family when she came rockin' an extra chromosome. She spent days in the NICU and left with oxygen but seemed in good health other…

Education videos and webinars for healthcare professionals

Deepening Response of Bexmarilimab in Combination with SoC in Hematological Malignancies: BEXMAB Study Update

TURKU, FINLAND / BOSTON, MA - December , - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focus…

Haley

I was diagnosed on February , , with stage 3B nodular sclerosing Hodgkin lymphoma (NSHL). I was attending UNLV and working on finishing my prerequisit…

Ira

In August , at age , I was literally in the best shape of my life. I was an avid cyclist, averaging more than miles per week, leading groups of rider…

Jade

Last year in June of , I was diagnosed with acute lymphoblastic leukemia (ALL) at the age of . This diagnosis came as a complete shock to my family an…

Jane

In October , I was diagnosed with Hodgkin lymphoma. After growing up never getting sick, I had cancer. It was incredibly difficult to comprehend at th…

Jonathan

I was diagnosed with acute lymphoblastic leukemia (ALL) on July , , and even without the involvement of a pandemic, I imagine that’s reason enough to…

Karley

Back in , my sister Karley was diagnosed with acute lymphocytic leukemia (ALL). It was a huge shock to her and our family as up until that point she w…

Lorelai

I was diagnosed with acute myeloid leukemia (AML) when I was . Throughout my entire cancer journey, I had a lot of people in my corner. But what I fou…

Joe

After being diagnosed with acute lymphoblastic leukemia (ALL) in March of when I was only years old, my entire life changed and was put on hold. I w…

Mackenzie

I am a recipient of The Leukemia & Lymphoma Society’s (LLS) - Dreamers and Doers Scholarship for Blood Cancer Survivors. I was initially diagn…

Nicole

I first became involved in Team In Training (TNT) and The Leukemia & Lymphoma Society (LLS) in March of because I was very interested in running the …

Nikolette

I was truly honored to be a recipient of The Leukemia & Lymphoma Society (LLS) Scholarship for Blood Cancer Survivors. After fighting two different ty…

Roger

I'd like to share how when life looks dark, we never know what's over the horizon. Not quite eight years ago I was diagnosed with stage lymphoma with…

Affimed Provides Updated Clinical Data from Phase 1/2 Study from AFM13 Precomplexed Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting

Heidelberg, Germany, December , – Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a company committed to giving patients back their inna…

Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib at ASH Annual Meeting

SAN DIEGO, Dec. , - Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for th…